Journal of Dental Research publishes a paper directed by Salvatore Sauro, Professor at University CEU Cardenal Herrera in Spain, in collaboration with international researchers from Finland, Brazil, United States and United ...
Oct 22, 2014
0
0
An analysis of data from two randomized clinical trials finds that three to four years of treatment with bisphosphonates to improve bone density is not linked to reduced risk of invasive postmenopausal breast cancer.
Aug 11, 2014
0
0
Key studies released today at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) identify new strategies for easing the short- and long-term effects of cancer therapy and improving the quality of ...
Jun 2, 2014
0
0
Women with metastatic breast cancer to the bone may be able to receive bisphosphonates, the bone-targeting class of drugs like zoledronic acid, less often after the first year of monthly administration. With that practice ...
May 30, 2014
0
0
A study comparing the efficacy and tolerability of two popular osteoporosis drugs, denosumab and zoledronic acid, found that denosumab had a significantly greater effect on increasing spine bone mineral density and zoledronic ...
Nov 28, 2013
0
0
The risks of developing kidney failure and a calcium deficiency from the popular osteoporosis drug zoledronic acid are extremely rare, according to researchers at Loyola University Health System (LUHS). These findings were ...
Oct 31, 2013
0
0
Researchers at the University of Georgia have discovered that a combination of two commonly prescribed drugs used to treat high cholesterol and osteoporosis may serve as the foundation of a new treatment for toxoplasmosis, ...
Oct 17, 2013
0
0
(HealthDay)—Women with postmenopausal osteoporosis treated with zoledronic acid show an early increase in serum levels of the negative regulator of bone formation, sclerostin, that return close to baseline after 360 days, ...
Apr 29, 2013
0
0
Although the drug zoledronic acid slows bone loss in osteoporosis patients, it also boosts levels of a biomarker that stops bone formation, according to a recent study accepted for publication in The Endocrine Society's Journal ...
Apr 17, 2013
0
0
The initial study results of the Zometa European Study (ZEUS) showed no difference in the incidence of bone metastases between the Zometa group and control arm, said Prof. Manfred Wirth during the closing and fourth plenary ...
Mar 19, 2013
0
0
